Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
By N. Kalay, Emrullah Başar, I. Ozdoğru, O. Er, Yakup Çetinkaya, A. Dogan, Tuğrul Inanç, A. Oğuzhan, N. Eryol, R. Topsakal and 1 more. Journal of the American College of Cardiology, 2006
670 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/83571e05e27e5757350ae63b03054f7d9428d9a9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Oncology
Citations in the corpus
- Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. (2012, positive): “Kalay et al. [143] demonstrated that left ventricle diameters remained constant and diastolic function was better preserved after doxorubicin-treatment in patients receiving carvedilol, compared with placebo.”
- Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, background): “Moreover, in a recent linical trial, the use of carvedilol prophylactically protected ystolic and diastolic function compared with placebo in atients treated with anthracycline chemotherapy (67).”
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials (2010, background): “For carvedilol [74], L-cartinine [75], prenylamine [76], amifostine [77] and acetylcysteine [78] there was only one RCT for each agent.”
- Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol (2016, result): “This is in contrast to findings in some prior, small-scale, randomized studies.(14,15,17) Potential reasons for this apparent discrepancy include that patients in prior studies may have received higher doses of anthracyclines and had a higher prevalence of cardiovascular co-morbidities, which could ”
- Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment (2011, background): “In addition, in patients receiving high doses of doxorubicin (>500 mg/m 2 ), treatment with carvedilol prevented the decline in LVEF [77].”
- Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, positive): “This effect was confirmed in a randomized study in which prophylactic use of the drug protected both systolic and diastolic LV function in a small population of anthracycline-treated patients.(141) The protective effect of nebivolol, a beta-selective beta-blocker with a nitric oxide donor capacity, ”
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “There are a small number of studies to suggest that angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs) or selected beta blockers (BBs) such as carvedilol and nebivolol may be the preferred agents to reduce the risk of cardiotoxicity (Table 2).(65,66) In a single-”